ONLINE DATA SUPPLEMENT
Supplementary Table 1. Inclusion and exclusion criteria Inclusion criteria
Able to give informed consent (either from patient or next of kin) Age ≥18 years
Admission to Burn intensive care unit with ≥40% body surface burn or ≥20% body surface burn with inhalation injury
Admission to Trauma intensive care unit with Injury Severity Score* >15 and >4 units packed red blood cells within 24 hours
Admission to Medical intensive care unit with suspected or documented sepsis
Admission to Cardiac intensive care unit with a diagnosis of acute myocardial infarction Expected survival >72 hours
CMV seropositive
Exclusion criteria
Unable to give informed consent Age <18 years
Expected survival <72 hours
Use of antiviral agent cidofovir, foscarnet, ganciclovir, valacyclovir (HSV treatment doses of acyclovir, valacyclovir, or famciclovir permitted) within the last 7 days
Known or suspected underlying immune deficiency (transplant, congenital
immunodeficiency, receipt of immunosuppressive medications [prednisone, azathioprine, tacrolimus, cyclosporine, sirolimus, cyclophosphamide] within 30 days)
*As previously defined (1)
Supplementary Table 2. Definitions
Major infections included pneumonia or bacteremia
Pneumonia was diagnosed on the basis of radiographic pulmonary infiltrates and a quantitative bacterial culture of a bronchoalveolar lavage (>104 colony-forming units per milliliter).
An episode of clinically significant bacteremia was defined as signs or symptoms of infection (fever, leukocytosis) and isolation of a bacteria from at least one blood culture.
A single positive blood culture due to coagulase-negative staphylococci and other known common blood culture contaminants was excluded.
The Acute Physiology and Chronic Health Evaluation (APACHE) II score and the Injury Severity Score were calculated within 24 hours of admission to the ICU*
The term “immunocompetent” was used to describe patients lacking evidence of immunosuppression
Co-reactivation implies reactivation of both HHV-6 and CMV at any time during the study period, irrespective of the temporal sequence
*As previously defined (1, 2)
References:
1. Knaus WA, Draper EA, Wagner DP, et al.: APACHE II: a severity of disease classification system. [Internet]. Critical care medicine 1985; 13:818–29
2. Baker SP, O’Neill B, Haddon W, et al.: The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. [Internet]. The Journal of trauma 1974; 14:187–96
